Zobrazeno 1 - 10
of 49
pro vyhledávání: '"Keren Borensztajn"'
Autor:
Keren Borensztajn, Marie-Laure Sobrier, Philippe Duquesnoy, Anne-Marie Fischer, Jacqueline Tapon-Bretaudière, Serge Amselem
Publikováno v:
PLoS Genetics, Vol 2, Iss 9, p e138 (2006)
Splice site selection is a key element of pre-mRNA splicing. Although it is known to involve specific recognition of short consensus sequences by the splicing machinery, the mechanisms by which 5' splice sites are accurately identified remain controv
Externí odkaz:
https://doaj.org/article/4c6bbe7e7c014188a6e4d1c6aad461f0
Autor:
Fabienne Charbit‐Henrion, Roman Goguyer‐Deschaumes, Keren Borensztajn, Marc Mirande, Jérémy Berthelet, Fernando Rodrigues‐Lima, Anis Khiat, Marie‐Louise Frémond, Brigitte Bader‐Meunier, Marco M. Rodari, Luis Seabra, Gillian I. Rice, Marie Legendre, David Drummond, Laureline Berteloot, Charles‐Joris Roux, Nathalie Boddaert, Philippe Drabent, Thierry Jo Molina, Florence Lacaille, Manoelle Kossorotoff, Nadine Cerf‐Bensussan, Marianna Parlato, Alice Hadchouel
Publikováno v:
Charbit-Henrion, F, Goguyer-Deschaumes, R, Borensztajn, K, Mirande, M, Berthelet, J, Rodrigues-Lima, F, Khiat, A, Frémond, M-L, Bader-Meunier, B, Rodari, M M, Seabra, L, Rice, G I, Legendre, M, Drummond, D, Berteloot, L, Roux, C-J, Boddaert, N, Drabent, P, Molina, T J, Lacaille, F, Kossorotoff, M, Cerf-Bensussan, N, Parlato, M & Hadchouel, A 2022, ' Systemic inflammatory syndrome in children with FARSA deficiency ', Clinical Genetics, vol. 101, no. 5-6, pp. 552-558 . https://doi.org/10.1111/cge.14120
Clinical Genetics
Clinical Genetics, 2022, 101 (5-6), pp.552-558. ⟨10.1111/cge.14120⟩
Clinical Genetics
Clinical Genetics, 2022, 101 (5-6), pp.552-558. ⟨10.1111/cge.14120⟩
International audience; Variants in aminoacyl-tRNA synthetases (ARSs) genes are associated to a broad spectrum of human inherited diseases. Patients with defective PheRS, encoded by FARSA and FARSB, display brain abnormalities, interstitial lung dise
Publikováno v:
Current Opinion in Pulmonary Medicine
Current Opinion in Pulmonary Medicine, 2018, 24 (3), pp.253-259. ⟨10.1097/MCP.0000000000000471⟩
Current Opinion in Pulmonary Medicine, 2018, 24 (3), pp.253-259. ⟨10.1097/MCP.0000000000000471⟩
Purpose of review: Interstitial lung disease (ILD) in children (chILD) is an umbrella term for a heterogeneous group of rare respiratory disorders that are mostly chronic and associated with high morbidity and mortality. The pathogenesis of the vario
Autor:
Keren Borensztajn, Jan H. von der Thüsen, Cong Lin, Berend Isermann, Tom van der Poll, Hartmut Weiler, Chris A Spek
Publikováno v:
Journal of Cellular and Molecular Medicine
Journal of Cellular and Molecular Medicine, 20(11), 2029-2035. Wiley-Blackwell Publishing Ltd
Journal of cellular and molecular medicine, 20(11), 2029-2035. Wiley-Blackwell
Journal of Cellular and Molecular Medicine, 20(11), 2029-2035. Wiley-Blackwell Publishing Ltd
Journal of cellular and molecular medicine, 20(11), 2029-2035. Wiley-Blackwell
Coagulation activation accompanied by reduced anticoagulant activity is a key characteristic of patients with idiopathic pulmonary fibrosis (IPF). Although the importance of coagulation activation in IPF is well studied, the potential relevance of en
Publikováno v:
Expert Review of Respiratory Medicine
Expert Review of Respiratory Medicine, 2018, 12 (12), pp.1051-1060. ⟨10.1080/17476348.2018.1538795⟩
Expert Review of Respiratory Medicine, Taylor & Francis, 2018, 12 (12), pp.1051-1060. ⟨10.1080/17476348.2018.1538795⟩
Expert Review of Respiratory Medicine, 2018, 12 (12), pp.1051-1060. ⟨10.1080/17476348.2018.1538795⟩
Expert Review of Respiratory Medicine, Taylor & Francis, 2018, 12 (12), pp.1051-1060. ⟨10.1080/17476348.2018.1538795⟩
International audience; Introduction: Children interstitial lung disease (chILD) is a heterogeneous group of rare respiratory disorders characterized by inflammatory and fibrotic changes of the lung parenchyma. They include ILD related to exposure/en
Autor:
Valérie Nau, Emilie Filhol-Blin, Violaine Giraud, Laurent Gouya, Philippe Duquesnoy, Christophe Delacourt, Afifaa Butt, Jean-Charles Dalphin, Julie Traclet, Philippe Reix, Hilario Nunes, Bruno Crestani, Juliette Albuisson, Serge Amselem, Paul De Vuyst, Bruno Copin, Marie Legendre, Carine Gomez, Grégoire Prévot, Diane Bouvry, Raphael Borie, Clément Picard, Florence Dastot-Le Moal, Vincent Cottin, Caroline Kannengiesser, Nadia Nathan, Keren Borensztajn, Aurore Coulomb L'Hermine, Annick Clement, Kais Ahmad, Nathalie Allou, Martine-Louise Reynaud-Gaubert
Publikováno v:
Rare ILD/DPLD.
Background: Heterozygous mutations in the SFTPA1 and SFTPA2 genes, encoding the surfactant protein SP-A1 and SP-A2 have been associated with rare forms of familial IIP and lung adenocarcinoma. We previously described 11 new heterozygous SFTPA1 and SF
Autor:
Tom van der Poll, Cong Lin, Joost Daalhuisen, Bruno Crestani, Marieke S. ten Brink, C. Arnold Spek, Keren Borensztajn, Jan H. von der Thüsen
Publikováno v:
Journal of Cellular and Molecular Medicine, 19(6), 1346-1356. Wiley-Blackwell Publishing Ltd
Journal of cellular and molecular medicine, 19(6), 1346-1356. Wiley-Blackwell
Journal of Cellular and Molecular Medicine
Journal of cellular and molecular medicine, 19(6), 1346-1356. Wiley-Blackwell
Journal of Cellular and Molecular Medicine
Idiopathic pulmonary fibrosis is the most devastating diffuse fibrosing lung disease of unknown aetiology. Compelling evidence suggests that both protease-activated receptor (PAR)-1 and PAR-2 participate in the development of pulmonary fibrosis. Prev
Autor:
Tom van der Poll, Farhad Rezaee, Cong Lin, Keren Borensztajn, C. Arnold Spek, Maaike Waasdorp, Kun Shi
Publikováno v:
Oncotarget, 6(34), 35304-35314. Impact Journals LLC
Oncotarget, 6(34), 35304-35314. Impact Journals
Oncotarget
Oncotarget, 6(34), 35304-35314. Impact Journals
Oncotarget
Idiopathic pulmonary fibrosis (IPF) is a destructive disease in part resulting from premature or mature cellular aging. Protease-activated receptor-1 (PAR-1) recently emerged as a critical component in the context of fibrotic lung diseases. Therefore
Autor:
Venerino Poletti, Ulrich Costabel, Vincent Cottin, Keren Borensztajn, Bruno Crestani, Athol U. Wells, Wim A. Wuyts, Katerina M. Antoniou, Carlo Vancheri, Toby M. Maher, Luca Richeldi, Jan C. Grutters
Publikováno v:
The Lancet Respiratory Medicine. 2:933-942
Findings from recently published placebo-controlled trials in idiopathic pulmonary fibrosis have established that pirfenidone and nintedanib prevent about 50% of the decline in forced vital capacity typically seen in this disease; future trials are t
Publikováno v:
Mechanisms of Lung Injury and Repair.
Idiopathic pulmonary fibrosis (IPF) is a devastating lung disease, characterized by accumulation of extracellular matrix (ECM) proteins. Matrix metalloprotease 1 (MMP-1) is an endopeptidase capable of degrading ECM proteins like fibrillar collagens,